

### PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

## **Growth Hormones**

Phone: 800-728-7947 Fax back to: 866-880-4532

Patient Name:	Prescriber Name: Supervising Physician:			
Member/Subscriber Number:	Fax:	Phone:		
Date of Birth:	Office Contact:			
Group Number:	NPI:	State Lic ID:		
Address:	Address:			
City, State ZIP:	City, State ZIP:			
Primary Phone:	Specialty/facility name (if applicable):			
Drug Name and Strength:				
Directions / SIG:				
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.				
Q1. Is this being prescribed by an endocrinologist or a pedi	atric endocrinologist?			
☐ Yes ☐ No				
Q2. What is the patient's age?				
☐ Greater than 18 years (go to question 3)				
☐ Less than or equal to 18 years (go to question 10)				
Q3. Adults: For what diagnosis is this drug being prescribed (pick one)?				
☐ Growth hormone deficiency (GHD)				
☐ Other				
Q4. Does the patient have irreversible hypothalamic-pituitary disease (etiologies may include radiation therapy, surgery,				
or trauma)?				
☐ Yes ☐ No				
Q5. Does the patient have low IGF-1 level (e.g. less than 2.5 percentile or less than -2 standard deviations)?				
☐ Yes ☐ No				
Q6. Does the patient have a negative response to GH stimulation testing (peak GH < $5 \mu g/L$ ) based on insulin tolerance test? (Acceptable alternative stimulation tests: growth hormone releasing hormone (GHRH) + arginine (ARG), glucagon or ARG)				



## PRIOR AUTHORIZATION REQUEST FORM EOC ID:

## **Growth Hormones**

Phone: 800-728-7947 Fax back to: 866-880-4532

Detient Name	Prescriber Name:		
Patient Name:	Supervising Physician:		
☐ Yes ☐ No			
Q7. Has the patient previously been treated for Childhood-C	Onset Growth Hormone Deficiency (COGHD) with GH		
therapy?			
☐ Yes ☐ No			
Q8. Does the patient have pan-hypopituitarism (greater that	n or equal to 3 pituitary hormone deficiencies)?		
☐ Yes ☐ No			
Q9. Does the patient have low IGF-1 level (e.g. less than 2.	5 percentile or less than -2 standard deviations)?		
☐ Yes ☐ No			
Q10. Pediatrics: For what diagnosis is this drug being preso	cribed (pick one)?		
☐ Growth hormone deficiency (GHD)			
☐ Turner syndrome (TS)			
☐ Small for gestational age (SGA)			
$\square$ Growth failure in children with chronic renal insufficiency	1		
☐ Prader-Willi syndrome (PWS)			
$\square$ Noonan syndrome (and other FDA-approved dwarfing s	yndromes)		
☐ Other			
Q11. Please provide ICD code(s) for diagnosis.			
Q12. Pediatrics: Is this request for a patient being newly sta	arted on GH therapy for GHD?		
☐ Yes ☐ No			
Q13. Pediatric GHD new start: Does the patient have market	ed short stature defined as height less than 3rd percentile		
(e.g. > 2 standard deviations (SD) below the mean for age a	and gender)?		
☐ Yes ☐ No			
Q14. Pediatric GHD new start: Does the patient have growt	h failure defined as height velocity less than 3rd percentile		
(e.g. < 2 SD below mean for age)?			
☐ Yes ☐ No			
Q15. Pediatric GHD new start: Does the patient have less s	severe short stature combined with moderate growth failure		
(e.g. growth velocity < 15th percentile or less than 1 SD)?			
☐ Yes ☐ No			
Q16. Pediatric GHD new start: Does the patient have a doc			
levels (e.g. values > 2 SD below the mean for IFG-1 or IFGB-3)?			



### PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

## **Growth Hormones**

Phone: 800-728-7947 Fax back to: 866-880-4532

		Prescriber Name:	
Patient Name:		Supervising Physician:	
□ Yes	□ No		
	ew start: Does the patient have diminsts: arginine, glucagon, or clonidine?	ished serum growth hormone level based on TWO of the	
□ Yes	□ No		
Q18. Pediatric GHD co	ontinuation: Does the patient have a	documented epiphyseal closure?	
□ Yes	□ No		
Q19. Pediatric GHD co	ontinuation: Does the patient have a g	growth rate velocity of greater than or equal to 2.5 cm/year?	
□ Yes	□ No		
Q20. Pediatrics: Is this request for a patient being newly started on GH therapy for TS?			
□ Yes	□ No		
Q21. Pediatric TS new start: Has the patient been diagnosed with TS using chromosome analysis?			
☐ Yes	□ No		
Q22. Pediatric TS new start:Does the patient have short stature?			
☐ Yes	□ No		
Q23. Pediatric TS cont	inuation: Does the patient have a bo	ne age of greater than or equal to 14 years of age?	
☐ Yes	□ No		
Q24. Pediatrics: Is this	request for a patient being newly sta	arted on GH therapy for SGA?	
☐ Yes	□ No		
Q25. Pediatric SGA new start: Has the patient's height remained less than 3rd percentile (e.g. > 2 SDS below the mean for age and sex) at 2 years of age?			
□ Yes	□ No		
Q26. Pediatric SGA co	ntinuation: Does the patient have a g	growth rate velocity of greater than or equal to 2.5 cm/year?	
☐ Yes	□ No		
Q27. Pediatrics: Is this insufficiency?	request for a patient being newly sta	arted on GH therapy for growth failure due to chronic renal	
☐ Yes	□ No		
	renal insufficiency new start: Has groen adequately stabilized and prior to	owth failure persisted after other factors contributing to uremic kidney transplantation?	
□ Yes	□ No		
Q29. Pediatric chronic	renal insufficiency continuation: Doe	s the patient have a documented epiphyseal closure?	



## PRIOR AUTHORIZATION REQUEST FORM EOC ID:

## **Growth Hormones**

Phone: 800-728-7947 Fax back to: 866-880-4532

	Prescriber Name:			
Patient Name:	Supervising Physician:			
☐ Yes ☐ No				
Q30. Pediatric chronic renal insufficiency continuation: Ha	s the patient had a renal transplant?			
☐ Yes ☐ No				
Q31. Pediatrics: Is this request for a patient being newly started on GH therapy for PWS?				
□ Yes □ No				
Q32. Pediatric PWS new start: Has the patient been diagnosed with PWS using chromosome analysis and/or appropriate genetic evaluation?				
□ Yes □ No				
Q33. Pediatric PWS new start: Does the patient have grow	vth failure?			
□ Yes □ No				
Q34. Pediatric PWS new start: Is the patient's weight greater than 225% of ideal body weight (e.g. severely obese)?				
☐ Yes ☐ No				
Q35. Pediatric PWS new start: Does the patient have respiratory impairment or sleep apnea (evaluated by polysomnography)?				
□ Yes □ No				
Q36. Pediatric PWS continuation: Does the patient have a	documented epiphyseal closure?			
□ Yes □ No				
Q37. Pediatric PWS continuation: Has the patient had new onset respiratory impairment or sleep apnea?				
□ Yes □ No				
Q38. Pediatrics: Is this request for a patient being newly started on GH therapy for Noonan syndrome (or other FDA-approved dwarfing syndromes)?				
□ Yes □ No				
Q39. Pediatric dwarfing syndrome new start: Does the patient have short stature?				
☐ Yes ☐ No				
Q40. Pediatric dwarfing syndrome continuation: Does the patient have a documented epiphyseal closure?				
☐ Yes ☐ No				
Q41. Additional Comments				



# PRIOR AUTHORIZATION REQUEST FORM EOC ID:

## **Growth Hormones**

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.		
	Prescriber Name:	
Patient Name:	Supervising Physician:	
Prescriber Signature	Date	
□ Expedited/Urgent - By checking this box and signing above seriously jeopardize the life or health of the enrollee or the e	ve, I certify that applying the standard review timeframe may enrollee's ability to regain maximum function	
	essity denial. Requesting providers may speak to the SWHP medical nity to help impact the decision on a request before coverage has been	
entity named above. The authorized recipient of this information is prohibited from dis	hat is legally privileged. This information is intended only for the use of the individual or closing this information to any other party. If you are not the intended recipient, you are o the contents of this document is strictly prohibited. If you have received this telecopy in	